Antiretroviral Treatment Uptake and Adherence Among Men Who Have Sex With Men and Transgender Women With HIV in Mumbai, India: A Cross-Sectional Study

Christopher Piña, MD
Alpana Dange, MS
Shruta Rawat, MS
Urmi Jadhav, SSC
Julia H. Arnsten, MD, MPH
Rosy Chhabra, PsyD
Viraj V. Patel, MD, MPH*

Key words: adherence, antiretroviral therapy (ART), HIV, India, men who have sex with men (MSM), transgender women

India is home to the third largest number of people living with HIV (PLWH) in the world, with the epidemic disproportionately affecting men who have sex with men (MSM) and transgender women (TGW; AVERT, 2016). In 2013, HIV prevalence among Mumbai MSM (9.91%) was 10 times higher than in the general Mumbai population (<1%). While there are state-funded HIV prevention interventions for MSM and TGW in India, including efforts by India’s National AIDS Control Organization, few programs have specifically focused on antiretroviral therapy (ART) uptake and adherence for MSM or TGW living with HIV (Ministry of Health and Family Welfare Government of India, 2013a). Although India has made great strides toward addressing the HIV epidemic, with a 57% decline in infection rates between 2001 and 2011, the focus of these efforts remains on containment, with significantly less attention to care for and support PLWH (Ministry of Health and Family Welfare Government of India, 2013a).

Of the estimated 2.1 million PLWH in India, only 36% are taking ART (Joint United Nations Programme on HIV/AIDS, 2013). To support treatment scale-up, prevent ART resistance, and prevent new HIV infections (based on the treatment-as-prevention paradigm), robust support is needed for ART uptake and adherence by those already taking ART.

Christopher Piña, MD, is a medical resident, Primary Care/Social Internal Medicine residency program, Albert Einstein College of Medicine/Montefiore Health System, Bronx, New York, USA. Alpana Dange, MA, MPhil, is Research Director, The Humsafar Trust, Mumbai, India. Shruta Rawat, MSc, is the Research Manager, The Humsafar Trust, Mumbai, India. Urmi Jadhav, SSC, is the transgender community point of contact and a research assistant, The Humsafar Trust, Mumbai, India. Julia Arnsten, MD, MPH, is Chief, Division of General Internal Medicine, and Professor of Medicine, Psychiatry & Behavioral Sciences, and Epidemiology & Population Health, Albert Einstein College of Medicine/Montefiore Health System, Bronx, New York, USA. Rosy Chhabra, PsyD, is Research Associate Professor, Department of Pediatrics, and a faculty researcher, Albert Einstein College of Medicine/Montefiore Health System, Bronx, New York, USA. Viraj Patel, MD, MPH, is Assistant Professor of Medicine and a clinician-investigator, Division of General Internal Medicine, and a faculty member, Primary Care/Social Internal Medicine residency program, Albert Einstein College of Medicine/Montefiore Health System, Bronx, New York, USA. (*Correspondence to: . vpatel@montefiore.org).
living with HIV (Machtinger & Bangsberg, 2005; Rodger et al., 2016). No studies have specifically examined factors affecting ART use in MSM or TGW living with HIV in India. To address this, we conducted a survey study to better understand factors associated with ART adherence and inform interventions to optimize HIV treatment outcomes at a community-based organization (CBO) serving sexual and gender minority populations in Mumbai, India.

Methods

Design and Setting

We conducted a cross-sectional, interviewer-administered survey study to MSM and TGW living with HIV and accessing services from a PLWH support program at the Humsafar Trust (HST), one of India’s first CBOs focusing on gender and sexual minority populations located in Mumbai, India. HST provides a broad array of social and health services, including onsite HIV and syphilis testing and counseling, sexually transmitted infection treatment, basic primary care services, and mental health counseling. HST also houses Sanjeevani, a PLWH support group that provides linkage to treatment, basic navigation, and social support services. Surveys were conducted between July and September 2014. During this time, ART eligibility in India included either a CD4+ T cell lower than 350 cells/mm³ or a clinical stage III or IV according to the World Health Organization (Ministry of Health and Family Welfare Government of India, 2013b). The institutional review boards of Albert Einstein College of Medicine and the HST approved the study.

Participants

Inclusion criteria for participants in the study were (a) living with HIV infection, (b) MSM or hijra/transgender individual, (c) greater than 18 years of age, (d) ever had sexual contact with other men or hijra/transgender women, (e) registered client of HIV support program, (f) on ART, and (g) able to provide informed consent.

Recruitment and Procedures

Potential participants were identified by peer outreach staff from Sanjeevani, who then contacted them by phone or in person to verify inclusion criteria, provide information about the study, and schedule research visits. Research visits were conducted in private rooms at a separate satellite location operated by HST to maintain confidentiality. After obtaining informed consent, two trained PLWH outreach workers administered surveys in Hindi, which took approximately 25 minutes. Participants were compensated 200 rupees (approximately $3.50 USD) as an incentive, an amount deemed appropriate by the peer outreach staff and HST’s Institutional Review Board. All participants had the opportunity to meet with adherence counselors after survey completion.

Survey Development

We iteratively developed the survey by first identifying potential factors affecting ART adherence in other populations in India (Joglekar et al., 2011; Logie, Newman, Chakrapani, & Shunmugam, 2012; Patel, Mayer, & Makadon, 2012; Steward et al., 2008; Thomas et al., 2005) and in MSM/TGW in other developing countries (Mills, Nachega, Bangsberg, et al., 2006; Mills, Nachega, Buchan, et al., 2006). Next, HST’s HIV counseling staff and peer outreach workers (n = 4) ranked each identified potential factor according to its perceived impact on adherence. We then pilot tested the survey with feedback from peer staff members. The survey and informed consent forms were translated from English into Hindi by a professional translation company, and the translated versions were reviewed and revised for conceptual synchrony, comprehension, and acceptability by bilingual HST staff (all native Hindi speakers).

Outcome Measures

ART eligibility and uptake. To evaluate antiretroviral uptake, we tabulated data from a registry of clients accessing the HIV support program at HST. We determined the number of clients currently served, number eligible for ART, and number currently taking ART.
**ART adherence.** We measured self-reported adherence in the previous month and in the previous 3 months using the questions: Please think back at the last MONTH. Please tell me how many pills have you missed? and In the last 3 MONTHS, about how many pills have you missed? We defined nonadherence, our primary outcome, as missing any doses (i.e., <100% adherence) for each time period (Ekstrand, Chandy, Heylen, Steward, & Singh, 2010).

**Factors Associated With Adherence**

**Participant characteristics.** We collected data on age, gender, education, income, marital status (specifically, if currently married to a cis-gender woman), treatment access (government ART center or other), years on ART, and current medication side effects. We also measured sexual identity specific to the Indian context: MSM or gay, bisexual, kothi (MSM with traditionally more passive/receptive role), panthi (MSM with traditionally more dominant/insertive role), double-decker (MSM who practice both insertive and receptive intercourse), and hijra (often but not always considered to be a transgender person; Asthana & Oostvogels, 2001; Khan & Khan, 2006; Shinde, Setia, Row-Kavi, Anand, & Jerajani, 2009).

**Psychological factors.** We measured four psychological factors thought to impact adherence: (a) depressive symptoms, using the well-validated Center for Epidemiological Studies Depression Scale (CES-D 10; Cronbach’s alpha = 0.81), with scores of 10 or higher considered positive for clinically significant depression; (b) medication beliefs, using the Beliefs About Medicines Questionnaire (Cronbach’s alpha = 0.78; Horne, Weinman, & Hankins, 1999), with higher scores indicating more negative beliefs; (c) adherence-related self-efficacy, using the HIV Treatment Adherence Self-Efficacy Scale (Cronbach’s alpha = 0.86; Johnson et al., 2007) with higher scores indicating more self-efficacy; and (d) internalized homophobia, using the Internalized Homophobia Scale, modified to have transgender-inclusive language (Cronbach’s alpha = 0.60), with higher scores representing more internalized stigma (Meyer, 1995).

**Reasons for Nonadherence**

If a participant was nonadherent, at either 1 or 3 months, we asked those individuals about five common reasons for nonadherence, as indicated by the counseling staff, to understand why the participant may have missed a dose: (a) unable to obtain medication refills in time, (b) insufficient funds, (c) not having medications with them while traveling, (d) drinking alcohol, or (e) feeling healthy enough to skip medications. We also asked an open-ended question to elicit other reasons for nonadherence.

**Data Analysis**

To characterize the HIV care continuum in this sample, we calculated descriptive statistics to evaluate the proportion of the clients who were: (a) eligible for ART, (b) taking ART, (c) adherent at 1 month, and (d) adherent at 3 months. We then used chi-squared and analysis of variance tests to assess differences between those who were adherent and those who were nonadherent (using \( p < .10 \) to define significance due to the small sample size and exploratory nature of the study). We tabulated frequencies to describe reasons for nonadherence.

**Results**

**ART Uptake and Adherence**

Of the 300 individuals registered for and accessing HST’s HIV support services at the time of the study, 28% (85/300) were eligible for ART through government ART centers and 22% (65/300) were using ART at the time of the study. Of those eligible for ART, 76% (65/85) were taking ART. Nonadherence was common, however, with only 68% (44/65) reporting adherence in the previous 1 month and 52% (34/65) reporting adherence in the previous 3 months (Figure 1). Table 1 summarizes participant characteristics, stratified by past 3-month adherence status (nonadherent vs. adherent), for all 65 persons on ART. Their mean age was 38.4 \( (SD = 8.6) \), and almost all (97%) received free ART through government clinics and had been on ART for a mean of 4 years \( (SD = 8.6) \). Most were men (83%), with about half
identifying as gay or MSM (46%); many were married to a woman (40%), and most had completed secondary school (75%). The majority of participants (68%) screened positive for depression and 42% reported experiencing medication side effects.

Factors Associated With Adherence

In bivariate analyses, nonadherence at 3 months was associated only with younger age (35.8 ± 7 years vs. 40.8 ± 9.2 years, \( p = .015 \)) and having more negative beliefs about ART medications (Beliefs About Medicines Questionnaire = 13.1 ± 2.6 vs. 11.5 ± 2.7, \( p = .017 \)). Results were similar when the analyses were repeated for adherence in the previous 1 month (data not shown).

Reasons for Nonadherence

Of participants missing any doses \( (n = 31) \) in the previous 1 month or 3 months, 10/31 (32.2%) reported skipping doses due to drinking alcohol (i.e., not wanting to mix medications with alcohol), 9/31 (29%) indicated simply forgetting, 22.6% (7/31) indicated running out of medications before being able to obtain refills, 4/31 (12.9%) reported feeling healthy enough to skip doses, and 2/31 (3.1%) missed doses due to not having enough money.

Discussion

In this survey of MSM and TGW living with HIV infection and accessing support services at a CBO in Mumbai, India, we found relatively low rates of ART use and adherence by self-report. Overall, 28% were eligible for ART through government ART centers, and only 22% were using ART at the time of the study. However, of those eligible for ART based on CD4+ T cell count or World Health Organization stage, a high percentage (76%) were taking ART, but nonadherence was very common, with only 68% and 52% reporting adherence in the previous 1 and 3 months, respectively.

Another recent study of MSM in 12 Indian cities found ART uptake, among those who were eligible, to be approximately 16%, which was substantially lower than the 76% we observed (Mehta et al., 2015). Although this variation may likely be due to sampling differences, it may also be partly attributable to participants in our study, who were recruited through an HIV support program at a CBO for MSM/TGW that facilitated ART uptake by eligible clients.

Despite relatively high ART uptake by those who were eligible, we also noted potentially modifiable factors that could have impacted adherence. These included alcohol use, feeling healthy (i.e., decreased risk perception), and having negative attitudes toward ART medications, findings similar to those in other populations in India (Venkatesh et al., 2010). These findings support the need for routine screening for alcohol and substance use and dependence, and to associate counseling and treatment with these problems to help improve ART adherence and achieve better health outcomes. We also found that younger age was associated with nonadherence, consistent with other studies of adherence in India and globally (Gari et al., 2013). Possible reasons for nonadherence among younger individuals included not having experienced negative health consequences from HIV, not being used to taking medications regularly for any reason, having privacy concerns, having less of a regular day-to-day routine, or having other priorities, issues that are all potentially amenable to counseling.
This was an exploratory study and there were important limitations. First, we used self-reported adherence data. Second, the small sample size did not allow for multivariate analysis, and may potentially have masked correlates of adherence and differences between MSM and TGW. Lastly, our participants were from a pool of individuals accessing services at a lesbian, gay, bisexual, transgender, and questioning CBO, and the sample may not have been representative of the larger population of MSM and TGW living with HIV and using ART in Mumbai. Given that participants in our study were a part of a support network for MSM and TGW living with HIV, rates of ART use and adherence may have been higher in our sample than in those not connected in this way.

### Conclusion

This is one of the first studies to examine ART uptake and adherence by Indian MSM and TGW. While more in-depth studies are warranted to better understand factors impacting the HIV care continuum, evidence-based scalable interventions are urgently needed to optimize health outcomes for MSM and TGW living with HIV in India.

### Disclosures

The authors report no real or perceived vested interests that relate to this article that could be construed as a conflict of interest.

---

**Table 1. Participant Characteristics and Correlates of ART Adherence at 3 Months**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total (n = 65)</th>
<th>Nonadherent (n = 31)</th>
<th>Adherent (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Age (mean ± SD)</em></td>
<td>38.4 ± 8.6</td>
<td>35.8 ± 7</td>
<td>40.8 ± 9.2</td>
</tr>
<tr>
<td>Years on ART (mean ± SD)</td>
<td>4 ± 2.5</td>
<td>3.5 ± 2.2</td>
<td>4.4 ± 2.7</td>
</tr>
<tr>
<td>Received government-funded ART</td>
<td>63 (96.9%)</td>
<td>30 (96.8%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>54 (83.1%)</td>
<td>27 (87.1%)</td>
<td>27 (79.4%)</td>
</tr>
<tr>
<td>Transgender</td>
<td>11 (16.9%)</td>
<td>4 (12.9%)</td>
<td>7 (20.6%)</td>
</tr>
<tr>
<td>Sexual identity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gay/MSM</td>
<td>30 (46.2%)</td>
<td>14 (45.2%)</td>
<td>16 (27.1%)</td>
</tr>
<tr>
<td>Bisexual</td>
<td>9 (13.9%)</td>
<td>6 (19.4%)</td>
<td>3 (8.8%)</td>
</tr>
<tr>
<td>Kothi</td>
<td>9 (13.8%)</td>
<td>3 (9.7%)</td>
<td>6 (17.7%)</td>
</tr>
<tr>
<td>Panthi</td>
<td>2 (3.1%)</td>
<td>1 (3.2%)</td>
<td>1 (2.9%)</td>
</tr>
<tr>
<td>Double decker</td>
<td>4 (6.2%)</td>
<td>3 (9.7%)</td>
<td>1 (2.9%)</td>
</tr>
<tr>
<td>Hijra</td>
<td>11 (16.9%)</td>
<td>4 (12.9%)</td>
<td>7 (20.6%)</td>
</tr>
<tr>
<td>Married to a woman</td>
<td>25 (40.3%)</td>
<td>12 (38.7%)</td>
<td>13 (38.2%)</td>
</tr>
<tr>
<td>Highest school level completed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary</td>
<td>15 (25%)</td>
<td>8 (25.8%)</td>
<td>7 (20.6%)</td>
</tr>
<tr>
<td>Secondary or greater</td>
<td>45 (75%)</td>
<td>19 (61.3%)</td>
<td>26 (76.5%)</td>
</tr>
<tr>
<td>Monthly income (mean ± SD)</td>
<td>Rs. 9,041 ± 5,842</td>
<td>Rs. 8,216 ± 5,603</td>
<td>Rs. 9,794 ± 6,035</td>
</tr>
<tr>
<td>Side effects</td>
<td>27 (42.2%)</td>
<td>12 (38.7%)</td>
<td>15 (44.1%)</td>
</tr>
<tr>
<td><em>Medication beliefs (mean ± SD)</em></td>
<td>12.3 ± 2.8</td>
<td>13.1 ± 2.6</td>
<td>11.5 ± 2.7</td>
</tr>
<tr>
<td>Depression (CES-D-10 score mean ± SD)*</td>
<td>12.9 ± 5.2</td>
<td>13 ± 4.9</td>
<td>12.9 ± 5.6</td>
</tr>
<tr>
<td>Internalized homophobia (mean ± SD)</td>
<td>12.5 ± 3.1</td>
<td>12.7 ± 3.3</td>
<td>12.4 ± 3.1</td>
</tr>
<tr>
<td>Self-efficacy (mean ± SD)</td>
<td>97 ± 15.8</td>
<td>96.7 ± 17.7</td>
<td>97.3 ± 14.8</td>
</tr>
</tbody>
</table>

Note. ART = antiretroviral therapy; MSM = men who have sex with men; SD = standard deviation; Rs. = rupees.

*p < .05 for difference between nonadherent and adherent groups.

a. Not all categories add up to 100% due to missing data.
b. Perceived medications beliefs using the Beliefs About Medicines Questionnaire; range: 0-36.
d. Report of internalized stigma using Internalized Homophobia Scale, modified to have transgender-inclusive language; range 5-25.
Acknowledgments

We would like to acknowledge participants for their time, Sebastian Kohn, MS, and Jeremy Fagan, PhD, for their support during the editing process and manuscript preparation, and Santosh Karambe and Harish Kambli for their assistance in data collection. This study was supported in part by the Global Health Scholarship from the Rosenbluth Fund, Einstein’s Global Health Center, and National Institutes of Health K23-MH102118 (Principal Investigator: Viraj Patel, MD, MPH).

References


